Role of S100β Glial Protein as a Serological Marker for Analysis of Acute Ischemic Stroke

Kiran Buddharaju, M. Javali, A. Mehta, R. Srinivasa, P. Acharya
{"title":"Role of S100β Glial Protein as a Serological Marker for Analysis of Acute Ischemic Stroke","authors":"Kiran Buddharaju, M. Javali, A. Mehta, R. Srinivasa, P. Acharya","doi":"10.1177/25166085211011284","DOIUrl":null,"url":null,"abstract":"Background: Stroke is a major cause of neurological disability, which can be often predicted with serological markers. Glial-derived S100β protein is a potential biomarker for cerebral ischemia and may be helpful in predicting the severity, outcome, and recovery of stroke. Aim: This study aimed to study the role of S100β glial protein as a serological marker in predicting the severity of acute ischemic stroke (AIS), outcome, and functional recovery after 1 month. Methods: A hospital-based prospective case control study included 43 consecutive patients, >18 years old, who were admitted with acute middle cerebral artery (MCA) territory infarcts within 72 h of onset of neurological deficits. Control group comprised of 43 age-matched asymptomatic volunteers. Independent t-test and chi square test were used to compare the means and evaluate the association between protein level and various parameters. P ≤ .05 was statistically significant. Results: S100β protein level in AIS patients was significantly higher compared to controls (P < .05). Elevated serum S100β protein level was found to be associated with larger infarct volumes, higher National Institute Health Stroke Scale scores, and higher modified Rankin Scale scores at admission (P < .05). Patients with higher S100β protein levels at admission had poor recovery at 1 month compared to patients having normal S100β protein levels. Conclusion: S100β protein levels at admission after an acute MCA territory infarct may be used as a reliable serological tool in predicting the severity, outcome, and functional recovery in stroke.","PeriodicalId":93323,"journal":{"name":"Journal of stroke medicine","volume":"7 1","pages":"58 - 63"},"PeriodicalIF":0.0000,"publicationDate":"2021-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of stroke medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/25166085211011284","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Stroke is a major cause of neurological disability, which can be often predicted with serological markers. Glial-derived S100β protein is a potential biomarker for cerebral ischemia and may be helpful in predicting the severity, outcome, and recovery of stroke. Aim: This study aimed to study the role of S100β glial protein as a serological marker in predicting the severity of acute ischemic stroke (AIS), outcome, and functional recovery after 1 month. Methods: A hospital-based prospective case control study included 43 consecutive patients, >18 years old, who were admitted with acute middle cerebral artery (MCA) territory infarcts within 72 h of onset of neurological deficits. Control group comprised of 43 age-matched asymptomatic volunteers. Independent t-test and chi square test were used to compare the means and evaluate the association between protein level and various parameters. P ≤ .05 was statistically significant. Results: S100β protein level in AIS patients was significantly higher compared to controls (P < .05). Elevated serum S100β protein level was found to be associated with larger infarct volumes, higher National Institute Health Stroke Scale scores, and higher modified Rankin Scale scores at admission (P < .05). Patients with higher S100β protein levels at admission had poor recovery at 1 month compared to patients having normal S100β protein levels. Conclusion: S100β protein levels at admission after an acute MCA territory infarct may be used as a reliable serological tool in predicting the severity, outcome, and functional recovery in stroke.
S100β胶质蛋白作为急性缺血性脑卒中血清学指标的作用
背景:中风是神经功能障碍的主要原因,通常可以用血清学标志物预测。神经胶质源性S100β蛋白是脑缺血的潜在生物标志物,可能有助于预测中风的严重程度、预后和恢复。目的:本研究旨在研究S100β胶质蛋白作为血清学标志物在预测急性缺血性卒中(AIS)严重程度、预后和1个月后功能恢复中的作用。方法:一项以医院为基础的前瞻性病例对照研究,纳入了43例连续患者,年龄>18岁,在神经功能障碍发病72小时内因急性大脑中动脉(MCA)区域梗死而入院。对照组由43名年龄相匹配的无症状志愿者组成。采用独立t检验和卡方检验比较均数,评价蛋白水平与各参数的相关性。P≤0.05有统计学意义。结果:AIS患者S100β蛋白水平明显高于对照组(P < 0.05)。血清S100β蛋白水平升高与入院时更大的梗死面积、更高的nih卒中量表评分和更高的修正Rankin量表评分相关(P < 0.05)。入院时S100β蛋白水平较高的患者与S100β蛋白水平正常的患者相比,1个月后恢复较差。结论:急性中动脉区域梗死入院时S100β蛋白水平可作为预测卒中严重程度、预后和功能恢复的可靠血清学工具。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信